Aug 22, 2025 • Zacks Commentary
NEUTRAL
NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer
NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.
Jul 28, 2025 • Benzinga
SOMEWHAT-BULLISH
Top 3 Health Care Stocks That May Explode In July - HCA Healthcare ( NYSE:HCA ) , Molina Healthcare ( NYSE:MOH )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Jul 24, 2025 • Motley Fool
NEUTRAL
NovoCure Q2 Revenue Jumps 6 Percent
NovoCure ( NASDAQ:NVCR ) , the oncology device firm advancing Tumor Treating Fields therapy, released its second quarter 2025 results on July 24, 2025. GAAP revenue totaled $158.8 million in Q2 2025, an increase of 6% year over year and surpassing the $154.16 million analyst consensus ( GAAP ) .
Jul 24, 2025 • Motley Fool
NEUTRAL
Novocure: Steady Ahead of Key Milestones
Here's our initial take on Novocure's ( NASDAQ: NVCR ) fiscal 2025 second-quarter financial report.Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both revenue and loss per share topping Wall Street expectations.
Jul 24, 2025 • Zacks Commentary
NEUTRAL
NovoCure ( NVCR ) Reports Q2 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of +7.69% and +3.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 08, 2025 • Benzinga
SOMEWHAT-BULLISH
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - BrightSpire Capital ( NYSE:BRSP ) , Bluerock Homes Trust ( AMEX:BHM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.